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Summary 
Malignant tumor cells can escape CD8 + cytotoxic T cell killing by downregulating class I major 
histocompatibility complex (MHC) expression. Stable class I MHC surface expression requires 
loading of the heavy chain/light chain dimer with antigenic peptide, which is delivered to class 
I MHC molecules in the endoplasmic reticulum by the presumed peptide transporter, encoded 
by the transporter associated with antigen presentation (TAP) 1 and 2 genes. We have investigated 
whether loss of class I MHC expression frequently observed in different cancers could result 
from interference with TAP function. A polyclonal antiserum, raised against a bacterial glutathione 
S-transferase/human TAP-1 fusion protein, was used for the immunohistochemical analysis of 
TAP-1 expression in 76 cervical carcinomas. Results showed loss of TAP-1 expression in neoplastic 
cells in 37 out of 76 carcinomas. Immunohistochemical double staining procedures in combination 
with HLA-specific antibodies revealed congruent loss at the single cell level of TAP-1 and HLA- 
A/B expression in 28 out of 37 carcinomas. The remaining samples expressed HLA(-A) in the 
absence of TAP-1 (n  =  6) or showed loss of HLA(-A/B) while TAP-1 was expressed (n  =  3). 
These data strongly indicate that inhibition of peptide transport by downregulation of TAP-1 
is a potential strategy of malignant cells to evade immune surveillance. 
T 
he transporter associated with antigen presentation (TAP) 
is encoded by the TAP-I and -2 genes (1, 2), located within 
the class II MHC region. Their products share structural prop- 
erties with members of the superfamily of ATP-binding trans- 
porters (2, 3) and their function is to translocate antigenic 
peptide from the cytosol into the endoplasmic reticulum (Elk). 
There, class I H chain, L chain (B2-microglobulin),  and pep- 
tide assemble into a complex which is then transported to 
the cell surface. Mutant cell lines (4,  5) or mice (6) lacking 
TAP-1  and/or -2 genes do not present antigen to CD8 + T- 
cells and show strongly reduced levels of surface class I MHC 
molecules, indicating that peptide should be considered the 
essential  third subunit of the class I complex (7-9).  Upon 
viral infection or malignant cell transformation, the ensuing 
alternations in gene expression result in the generation of 
novel sets of peptides available for binding to class I MHC 
products. These are potential targets for CD8 + CTLs (10, 
11) and can play a pivotal role in the eradication of vitally 
or transformed cells. Loss of class I MHC expression has been 
observed frequently in malignant cells of different origin (12) 
and in virally transformed ceils (13). Such loss would allow 
these cells to escape from CTL-mediated killing and conse- 
quently increase their oncogenic potential. Downregulation 
of class I MHC surface expression is often related to tran- 
scriptional inhibition of H  (14, 15) or L (16) chain gene ex- 
pression. In virally infected cells, additional posttranscriptional 
mechanisms may result in the retention of class I MHC com- 
plexes in the ER, such as binding of H chains by the adenovirus 
E3 glycoprotein (17,  18) or binding of H  and/or L chains 
by cytomegalovirus H301 (19) or other proteins (20) (Bijlmakers, 
M. J., T. Beersma, and H. L. Ploegh, unpublished observations). 
Besides deprivation of H  and/or L chains, the loss of pep- 
tide could also result in reduced class I MHC surface expres- 
sion.  Downregulation of class I MHC expression  has been 
found in a substantial number of cervical carcinomas, containing 
human papilloma-virus type 16 DNA (21, 22). Since the pres- 
ence of H  chain and 32-microglobulin transcripts was ob- 
served by RNA in situ hybridization in neoplastic cervical cells 
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scriptional  regulation has been postulated (23). Loss of TAP 
function and the consequent failure to produce stable class I 
MHC molecules  could be an explanation. Therefore in this 
study, class I MHC and TAP-1 expression were examined in 
76 carcinomas of the uterine cervix by immunohistochemistry 
with class I H chain-specific mAbs and a polyclonal antiserum 
raised against a bacterial glutathione~S-transferase  (GST)/human 
TAP-1 fusion protein. Double staining procedures were used 
to correlate the TAP-1 and class I MHC expression at the single 
cell level. 
Materials  and Methods 
TAP-I Immunoblotting.  A rabbit antiserum raised against the 
TAP-1 COOH-terminal domain, fused to GST (Airey,  J., M. T. 
Heemels, and H. L. Ploegh, unpublished observations) was used 
(1:1,000) to detect the TAP-1 protein in lymphoblastoid cells (LB), 
the human T-lymphoblastoid  T1 cell  line, and the TAP-1/-2-deficient 
T2 cell line. 5  x  10  s cells of each cell line were lysed in SDS 
sample buffer, and their proteins separated  by 10% SDS-PAGE and 
transferred to nitrocellulose. Incubation with a horseradish  peroxi- 
dase-conjugated anti-rabbit  antibody (1:1,000) followed by che- 
miluminescence (ECL system; all from Amersham International, 
Amersham, Bucks., UK) and exposure to film (X-AR 5; Eastman 
Kodak Co., Rochester, NY) were used to detect the antigen-anti- 
body complex. 
TAP-1/HLA  Immunohistochemistry.  Formalin-fixed, paraffin- 
embedded tissues (n =  16) were obtained from patients attending 
the oncological  gynecological  outpatient department from the Free 
University Hospital for routine diagnostic and therapeutic proce- 
dures. Snap-frozen tissues (n  =  60) were obtained from patients 
undergoing anesthesia  before radiotherapy  at the Christie Hospital. 
Immunohistochemical stainings were essentially performed as de- 
scribed (22). Briefly,  4-/~m-thick  paraffin  sections  were deparaffnized 
with xylene, rehydrated, and endogenous peroxidase was blocked 
by incubating for 30 rain with methanol, containing 0.3% H2Oz. 
After rinsing in PBS, pH 7.4, sections were pretreated as follows 
for  the  different  primary  antibodies: for  HCA2  and  rabbit 
anti-human TAP-1 sections were treated for 2  x  5 rain at 95~ 
with Target Unmasking Fluid (Kreatech,  Amsterdam, The Nether- 
lands); for Pan Keratin (Dako Patts, Glostrup, Denmark), sections 
were digested for 30 min at 37~  with trypsin (0.5% wt/vol) in 
0.5%  CaClz (pH  7.8); and for HC10, no pretreatment  was re- 
quired. Frozen sections (7/~m thick) were fixed for 10 rain in ace- 
tone  and  immediately  transferred  to  PBS, without  further 
pretreatment. 
After preincubation with the appropriate normal serum, sec- 
tions were incubated with the following primary antibodies: for 
paraffin sections, mAb HC-A2 (1:500) recognizing preferentially 
HLA-A locus products (24); mAb HC10 (1:1,000), reactive with 
HLA-B and -C locus products (24); polyclonal antibody Pan Ker- 
atin (1:400), recognizing a broad spectrum of cytokeratins;  and poly- 
clonal rabbit anti-human TAP-1 serum (1:400); for frozen sections, 
mAbs Bl16-5-28 and B126-30 (1:5), specific for HLA-Bw4 and 
-Bw6, respectively  (a generous gift from Dr. Gelsthorpe, National 
Blood Transfusion  Service, Sheffield,  UK); mAb W6/32 (1:20, Ser- 
alab Ltd., Sussex, UK), recognizing HLA-A, -B, and -C locus prod- 
ucts, complexed to/32-microglobulin; mAb 4E (1:10), binding to 
HLA-B, C and Awl9 (25); mAb HC10 (1:100); polyclonal rabbit 
anti-human TAP-1 serum (1:1,000); mAb LP34 (1:5) (Dako), specific 
for cytokeratins 6 and 18. 
After incubation, sections were washed repeatedly in 4 x  SSC 
(lx SSC = 0.15 M NaC1, 0.015 M Na-citrate), 1% (vol/vol) low- 
fat milk (for HC-A2 and rabbit anti-human Tap-l) or in PBS (HC10, 
Pan Keratin, Bl16, B126, W6/32, 4E, LP34). W6/32 and LP34 
were detected in a two-step method with horseradish peroxidase, 
coupled to rabbit anti-mouse antibody (Dako). All other antibodies 
were detected in a three-step method, using biotinylated secondary 
antibodies (Vector Laboratories, Inc., Burlingame, CA) and horse- 
radish peroxidase, conjugated to streptavidin (Dako). Signals  were 
visualized with diaminobenzidine (DAB) and H202, after which 
sections were counterstained with hematoxylin, dehydrated, and 
mounted in DePex (BDH,  Poole, UK). 
For immunohistochemical  double stainings  for TAP-1 and HLA-A 
and -B expression, sections were incubated simultaneously with 
rabbit anti-human TAP-1 antibody and HC-A2 or HC10, respec- 
tively. The  bound  TAP-1 polyclonal antibody was  detected as 
described, with signal development with DAB/H202. The HLA- 
specific mAb was detected with a biotinylated rabbit anti-mouse 
Fab antibody fragment (Dako) and alkaline  phosphatase, conjugated 
to  streptavidin (Boehringer Mannheim, Mannheim, Germany). 
Signal was developed  with naphthol AS-MX phosphate as substrate 
and Fast Blue BB as coupling agent in 0.2 M Tris-HC1 (pH 8.5), 
according to the method of Mason and Sammons (26). Sections 
were not counterstained, and mounted in Kaiser's glycerin gelatin 
(E. Merck, Darmstadt,  Germany). 
Results were interpreted by three independent observers. The 
keratin-specific antibodies were used to confirm that carcinoma  cells 
were of epithelial origin and to ascertain general epitope conserva- 
tion. Loss of class I MHC or TAP-1 expression was confirmed in 
an additional  experiment  and was classified  as positive, heterogenous, 
or negative, according to the criteria noted (see legend to Table 1). 
Results and Discussion 
Specificity of TAP-1 Serum.  The rabbit anti-human TAP-1 
serum recognizes a polypeptide of •80  kD in immunoblots 
on cell extracts from a panel of EBV-transformed  human lym- 
phoblastoid cell lines  (Fig.  1).  Specificity of the serum for 
TAP-1  protein was demonstrated by the lack of reactivity 
in Western blots from T2 cells, which are devoid of TAP-1 
protein (4, 5). Transfection with the TAP-1 cDNA restored 
reactivity with the anti-TAP-1 serum (27) (Heemels,  M. T., 
and H. L. Ploegh, unpublished observations).  Specificity of 
the immunocytochemical staining with the TAP-1 antiserum 
was further confirmed by the lack of staining of cytospins 
of TAP-1/-2-negative T2 cells (data not shown). 
TAP-I Immunohistochemistry.  The serum was used for im- 
munohistochemical detection of TAP-1 protein in formalin- 
fixed, paraffin-embedded (n  =  16), and acetone-fixed,  snap- 
frozen (n =  60) tissue sections of cervical carcinomas. Normal 
epithelial cells, present in the same section, and infiltrating 
cells of the immune system, always stained positively. In neo- 
plastic cells, three different TAP-1 expression patterns could 
be observed.  Complete loss of TAP-1 expression in virtually 
all  neoplastic cells  was  observed  in  4  out  of 16  paraffin- 
embedded and 11 out of 60 frozen carcinomas.  In 9 paraffin- 
embedded and 13 frozen carcinomas,  heterogeneous loss of 
TAP-1  expression  in neoplastic cells was found. Positively 
staining tumor areas could be observed adjacent to areas that 
dearly show loss of staining (Fig. 2 A). Staining for TAP-1 
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TAP-1 subunit on cell extracts from 
the EBV-transformed cell line LB, the 
cell  line  T1,  and  its  TAP-l-  and 
-2-deficient variant T2 (29, 30). The 
complete absence in the T2 extract of 
the  "~80 kD  polypeptide  corre- 
sponding  to  TAP-1 indicates  the 
specificity of the antiserum. 
protein was localized in the cytoplasm  (Fig.  2 B),  which  is 
in accordance with the proposed ER localization of the TAP-1 
subunit (28). The remaining three paraffin-embedded and 36 
frozen  carcinomas  were uniformly  positive for TAP-1  pro- 
tein. Preliminary RNA  in situ hybridization data employing 
a TAP-l-specific probe indicate that loss of staining for TAP-1 
protein  is  related  to  reduced  signals  for  TAP-1  mRNA 
(Cromme,  F.  V.,  and J.  M. M.  Walboomers,  unpublished 
observations), further confirming that negative immunohisto- 
chemical staining with the TAP-1  serum represents reduced 
steady  state levels  of TAP-1  protein. 
Correlation between TAP-1 and Class I MHC Expression.  The 
different staining patterns  for the TAP-1 protein in relation 
Table  1.  Patterns of Expression of TAP.I  and HLA  in Cervical Carcinomas 
Figure 2.  Immunohistochemical 
staining using rabbit anti-human 
TAP-1  serum  (A  and  B),  HC10 
(HLA-B/C  H  chains;  C),  and 
double staining with  rabbit anti- 
TAP-1 and HC10 (D) on paraffin- 
embedded tissue sections from a cer- 
vical carcinoma. (A and B) Low and 
high magnification, respectively, of 
staining for TAP-1 protein. Positive 
staining for TAP-1 is localized in the 
cytoplasm of some neoplastic areas 
(brown), whereas other adjacent areas 
clearly show loss  of staining.  (C) 
Staining for HLA-B locus products 
on the consecutive  tissue sections 
shows that areas with loss of TAP- 
I also exhibit loss of HLA-B expres- 
sion.  (D).  Double  staining  with 
HC10 (blue) and rabbit anti-TAP-1 
(brown). Membranous staining for 
HLA-B is  observed  only in  neo- 
plastic cells that also exhibit cyto- 
plasmic  staining  for  TAP-1. Re- 
maining cells are negative for both 
antigens. 
TAP  TAP 
phenotype  HC-A2  HC10  phenotype  W6/32  HC10* 
Paraffin  16  +  + /  -  -  +  + /  -  -  Frozen  60  +  + /  -  -  +  + /  - 
+  3  3  0  0  3  0  0  +  36  36  0  0  33  0  3 
+/-  9  0  7  2  0  9  0  +/-  13  1  11  1  0  11  2 
-  4  0  0  4  0  0  4  -  11  3  2  6  0  0  11 
Summary of the immunohistochemical staining results for TAP-1 and HLA expression of 76 cervical carcinomas (73 squamous cell and 3 adenocarcino- 
mas), as determined with antibodies HC-A2 (HLA-A), W6/32 (HLA-A/B/C), and HC10 (HLA-B/C). Three TAP-1/HLA phenotypes were recog- 
nized: positive ( + ), when virtually all cells are labeled; negative ( -  ), when virtually all neoplastic cells show loss of staining as compared to normal 
epithelial and infiltrating immune cells in the same section; heterogeneous (+/-  ),  when positively staining tumor areas were observed adjacent 
to negatively staining areas, usually between 25 and 75% of the neoplastic cells in a specimen.  When the TAP-1 and HLA phenotypes are identical 
(bold numbers), this indicates congruency at the single cell level. 
* Pattern confirmed with  antibodies 4E,  Bw4,  and Bw6. 
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A) and rabbit anti-TAP-1  (/3) on consecutive  tissue  sections  of  a snap-frozen 
cervical  carcinoma.  (A) Staining  with W6/32 clearly  shows  positive  mem- 
branous staining  of  neoplastic  cells  and infiltrating  immune  cells. (/3)  Cor- 
responding  neoplastic  area  is negative  for TAP-1 protein, whereas  immune 
cells exhibit cytoplasmic  staining. 
to class I MHC expression are summarized in Table 1. Class 
I MHC expression was studied on consecutive tissue sections 
using HLA-A and -B H chain locus-specific mAbs (HC-A2 
and HC10, respectively) in the paraffm-embedded specimens. 
Frozen tissues wire analyzed using an antibody recognizing 
complexed HLA-A/B/C locus products (W6/32) and anti- 
bodies specific mainly for HLA-B/C H  chains (HC10, 4E). 
In most cases, Bw4- and Bw6-specific antibodies confirmed 
the staining pattern obtained with HC10 and 4E, indicating 
that the latter two antibodies mainly react with B locus prod- 
ucts in immunohistochemistry. 
In general, the pattern of HLA expression was similar to 
that of TAP-l, as shown with HCI0 in Fig. 2 C. Areas that 
show loss of staining for TAP-1 (Fig.  2 A) are also negative 
for HLA-B (Fig. 2 C). Immunohistochemical double staining 
procedures revealed a simultaneous loss of  TAP-1 and HLA-B 
expression at the single cell level (Fig. 2 D). Staining for class 
I has predominantly a membranous localization (blue), whereas 
TAP-1 protein is detected in the cytoplasm of the same neo- 
plastic cells (brown). From the 37 carcinomas that show het- 
erogeneous or total loss of TAP-1 expression, HLA-B locus 
expression was congruently lost in 35 cases (Table 1, HC10 
column). No examples of expression of HLA-B locus prod- 
ucts with loss of TAP-1 protein were seen, indicating that 
cell surface expression of HLA-B alleles in vivo strongly de- 
pends on TAP functioning. 
However,  six carcinomas showed positive staining with 
W6/32 whereas TAP expression was lost (Table 1, i.e., four 
W6/32 positive and two W6/32 heterogenous carcinomas). 
A typical example is shown in Fig. 3. Neoplastic cells clearly 
exhibit positive staining with W6/32  (Fig.  3 A), whereas 
TAP-1 protein cannot be detected (Fig. 3 B). Since the iden- 
tical area is also negative for HLA-B/C expression (data not 
shown), at least some HLA-A alteles can probably be stably 
expressed at the cell surface in the absence of TAP-1 protein 
in cervical carcinomas. HLA serotyping of these six patients 
revealed  HLA-A2 positivity in  three cases (Keating,  P. J., 
F. V. Cromme, P. L. Stern, and P. A. Dyer, unpublished ob- 
servations). This is in accordance with the residual HLA-A2 
expression observed in the human T2 cell line,  which is de- 
void  of TAP-1  protein  (29,  30).  The expression  of other 
HLA-A alleles in the remaining three lesions indicates that 
additional A  locus products besides  HLA-A2 can be stabi- 
lized in the absence of TAP-1. 
Furthermore, eight carcinomas lack single cell congruency 
between TAP-1  and HLA expression,  since  they show re- 
duced levels of HLA-A or -B expression while TAP-1  pro- 
tein can be detected (Table 1, i.e., two HC-A2, one W6/32, 
and five HC10 negative cases). Because HLA-A and -B locus- 
specific transcripts could be detected in all carcinomas ana- 
lyzed with RNA in situ hybridization (23), additional post- 
transcriptional mechanisms besides loss of TAP-1 might be 
involved that interfere with peptide loading of class I MHC 
molecules in the ER. These may include loss ofpeptide pro- 
cessing, loss of TAP-2, or lack of additional cytosolic factors, 
necessary for peptide  translocation. 
In conclusion, results from this study indicate that down- 
regulation of peptide transport may constitute a mechanism 
by which malignant cells  escape  killing by CTL.  Absence 
of TAP-l/-2 expression accompanied by loss of class I MHC 
expression has recently been reported in small cell lung carci- 
noma cell lines (31). This report shows that this phenomenon 
occurs in human malignancies in situ.  In addition, the ob- 
served high  correlation between TAP-1  and class  I  MHC 
downregulation may to a large extent explain the posttran- 
scriptional control of class I MHC expression frequently ob- 
served in cervical carcinomas. Preliminary results on lung (n  = 
10), colon (n  =  5), and mammary (n  =  5) carcinomas indi- 
cate that loss of immunoreactivity for TAP-1 is not only re- 
stricted to cervical carcinomas, but seems to be a more general 
phenomenon. 
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